[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563035":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":20,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Alexis MOSCA, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","0187891646","alexis.mosca@aphp.fr",{"name":18,"role":14,"phone":15,"phoneExt":7,"email":19},"Emmanuelle ECOCHARD-DUGELAY, MD","emmanuelle.dugelay@aphp.fr",[21],{"facility":22,"status":7,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Robert Debre Hospital","Paris","75019","France","FR",{"type":28,"coordinates":29},"Point",[30,31],2.3488,48.85341,{"lat":31,"lon":30},[34,35],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":15,"phoneExt":7,"email":19},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100563035","intestinal-microbiota-and-visceral-pain-in-chronic-intestinal-pseudo-obstruction-syndrome-cipo-100563035",false,"NCT06610929","Intestinal Microbiota and Visceral Pain in Chronic Intestinal Pseudo-Obstruction Syndrome (CIPO)","Metabolites From the Intestinal Microbiota and Visceral Pain Associated With Chronic Intestinal Pseudo-obstruction (CIPO) in Children","METADOLOMIC","Inclusion Criteria:\n\n* Patient aged 1 to 21 years\n* Patient diagnosed with CIPO for at least 12 months (= patients meeting at least 2 of the following 4 criteria: 1. Recurrent episodes of intestinal dilatation, 2. Inability to maintain nutrition, 3. Intestinal neuromuscular alteration and 4. Genetic variants.)\n* Patient with an ileal or colonic digestive diversion\n* Signature of informed consent by both holders of parental authority and agreement in principle given orally by the subject;\n* Patients affiliated to a social security scheme\n\nExclusion Criteria:\n\n\\-","ALL","1 Year","21 Years",{"count":50,"type":51},30,"ESTIMATED","OBSERVATIONAL","Chronic Intestinal Pseudo-Obstruction Syndrome (CIPO) is a rare gastrointestinal motility disorder. CIPO evolves through iterative flare-ups that can be triggered by viral or bacterial infections, psychological stress, or malnutrition. All of these factors are associated with dysbiosis of the intestinal microbiota (IM). Many studies have associated visceral pain with dysbiosis of the IM, particularly in the context of irritable bowel syndrome (IBS), a painful pathology associated with transit disorders. The team in Dr. Cénac's laboratory has demonstrated the analgesic effect of a bacterial lipid produced by an intestinal bacterium in the context of IBS. The study hypothesize that CIPO patients have a taxonomic and functional dysbiosis of the IM responsible for hyperactivation of sensory neurons inducing visceral pain.",[55],"Intestinal Obstruction",[57],"Microbiota","NOT_YET_RECRUITING","2024-09-24",{"date":61,"type":62},"2024-09-26","ACTUAL",{"date":64,"type":51},"2024-10-01",{"date":66,"type":51},"2025-11-01",{"name":5,"class":6},1]